Initial prostate biopsy, in our prospective study, was scheduled for patients selected on the basis of PSA values or DRE results, and SelectMDx score was positive in 86.5% of PCa, 87.1% of csPCa, and in 26.2% of cases with no PCa at biopsy. This evidence concerns the gene KLK3 and posterior cortical atrophy.